Lucid Diagnostics Inc.(LUCD)

$1.00—

Chart

Lucid Diagnostics Inc.(LUCD)

NASDAQ

$1.00—

Chart Studio

LUCD(LUCD)

LUCD

Overview Fair Value Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q4 2026 EPS Estimate

$-0.04

Nov 11, 2026 · Reports before open

Revenue Estimate

$2M

Analyst Sentiment

Wall St. Consensus

Buy

6 analysts·Limited coverage

Score

6 Buy (100%)0 Hold (0%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

6100%

Hold

00%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$2.00

+100.0%

Consensus

$2.00

+100.0%

Bull

$2.00

+100.0%

12-Month Target Range6 analysts

$2.00$2.00$2.00

Current $1.00Consensus

Current Price

$1.00

Upside to Consensus

$1.00

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+153.08%

EPS—

FY2028

Rev+98.76%

EPS—

FY2029

Rev+10.82%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$7M	$17M	$33M	$37M	$52M
Low	$5M	$12M	$20M	$27M	$38M
High	$9M	$23M	$55M	$50M	$70M
EBITDA Avg	$-7M	$-17M	$-33M	$-37M	$-52M
Low	$-9M	$-23M	$-55M	$-50M	$-70M
High	$-5M	$-12M	$-20M	$-27M	$-38M
EBIT Avg	$-7M	$-17M	$-33M	$-37M	$-52M
Low	$-9M	$-23M	$-55M	$-50M	$-70M
High	$-5M	$-12M	$-20M	$-27M	$-38M
Net Income Avg	$-28M	$-19M	$-16M	$-9M	$-7M
Low	$-38M	$-27M	$-20M	$-13M	$-10M
High	$-17M	$-12M	$-12M	$-6M	$-5M
EPS Avg	$-0.26	$-0.18	$-0.16	$-0.09	$-0.07
Low	$-0.38	$-0.26	$-0.19	$-0.13	$-0.10
High	$-0.16	$-0.12	$-0.12	$-0.06	$-0.04
Analysts (Rev / EPS)	3 / 2	3 / 3	4 / 4	2 / 1	2 / 1

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027	Q1 2028	Q2 2028
Revenue Avg	$2M	$2M	$3M	$3M	$5M	$6M	$9M	$12M
Low	$2M	$2M	$3M	$3M	$4M	$5M	$9M	$11M
High	$2M	$2M	$3M	$4M	$5M	$6M	$10M	$13M
EBITDA Avg	$-2M	$-2M	$-3M	$-3M	$-5M	$-6M	$-9M	$-12M
Low	$-2M	$-2M	$-3M	$-4M	$-5M	$-6M	$-10M	$-13M
High	$-2M	$-2M	$-3M	$-3M	$-4M	$-5M	$-9M	$-11M
EBIT Avg	$-2M	$-2M	$-3M	$-3M	$-5M	$-6M	$-9M	$-12M
Low	$-2M	$-2M	$-3M	$-4M	$-5M	$-6M	$-10M	$-13M
High	$-2M	$-2M	$-3M	$-3M	$-4M	$-5M	$-9M	$-11M
Net Income Avg	$-10M	$-9M	$-9M	$-9M	$-8M	$-8M	—	—
Low	$-11M	$-10M	$-10M	$-10M	$-9M	$-9M	—	—
High	$-9M	$-8M	$-8M	$-8M	$-7M	$-7M	—	—
EPS Avg	$-0.05	$-0.05	$-0.05	$-0.05	$-0.04	$-0.04	—	—
Low	$-0.06	$-0.06	$-0.05	$-0.05	$-0.05	$-0.05	—	—
High	$-0.05	$-0.05	$-0.04	$-0.04	$-0.04	$-0.04	—	—
Analysts (Rev / EPS)	2 / 1	2 / 1	1 / 1	1 / 1	1 / 1	1 / 1	1 / —	1 / —

Earnings Surprises

Recent Analyst Actions

May 15, 2026Maxim Group

Lucid Diagnostics price target lowered to $2 from $3 at Maxim

Target:$2.00

+101.8%from $0.99

Mar 25, 2025BTIG

Lucid Diagnostics price target lowered to $2 from $2.50 at BTIG

Target:$2.00

+29.0%from $1.55

Nov 13, 2024Needham

Needham Reiterates Buy Rating on Lucid Diagnostics Inc (LUCD)

Target:$2.50

+216.5%from $0.79

May 14, 2024Canaccord Genuity

Canaccord Genuity Reiterates Buy Rating on Lucid Diagnostics Inc (LUCD)

Target:$3.00

+215.8%from $0.95

Apr 8, 2024BTIG

BTIG updates Lucid Diagnostics Inc (LUCD) model post Q4 results

Target:$2.50

+169.5%from $0.93

Nov 18, 2022BTIG

BTIG Maintains Buy on Lucid Diagnostics, Lowers Price Target to $3.5

Target:$3.50

+83.2%from $1.91

Nov 15, 2022Needham

Needham Maintains Buy on Lucid Diagnostics, Lowers Price Target to $3.1

Target:$3.10

+36.6%from $2.27

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance